Arca
Skip to content
Tools
Tools

PTGIR: Prostacyclin receptor

Receptor for prostacyclin (prostaglandin I2 or PGI2).

  • Drugs that act on it: 6
  • Approved: 4
  • In phases 1 to 3: 2
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on PTGIR, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 6

Approved4

  • Treprostinil
  • Epoprostenol
  • Selexipag
  • Iloprost

Phase 32

  • Ralinepag
  • Esuberaprost

Phase 20

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Lung Biotechnology PBC117%

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Prostanoid IP receptor agonist.
      TreprostinilApprovedUnited TherapeuticsSmall moleculeAgonist36
      EpoprostenolApprovedGSKSmall moleculeAgonist31
      SelexipagApprovedJohnson & JohnsonSmall moleculeAgonist11
      IloprostApprovedJohnson & JohnsonSmall moleculeAgonist10
      RalinepagPhase 3United TherapeuticsSmall moleculeAgonist1
      EsuberaprostPhase 3Lung Biotechnology PBCSmall moleculeAgonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 25 in all, from ClinicalTrials.gov.
      Local Iloprost Therapy to Promote Bone Healing in High Risk FracturesIloprostPhase 2Not yet recruitingCharite University, Berlin, GermanyNov 9, 2026
      Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)TreprostinilPhase 2Not yet recruitingUnited TherapeuticsNov 6, 2026
      An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)TreprostinilPhase 2 / Phase 3Not yet recruitingUnited TherapeuticsNov 6, 2026
      Colchicine in Pulmonary Artery Hypertension PatientsEpoprostenolPhase 2Not yet recruitingAin Shams UniversityOct 30, 2026
      PACE: Prostacyclin AntiCoagulation in ECMOEpoprostenolPhase 1 / Phase 2Not yet recruitingGarrett KeimSep 24, 2026
      Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH)TreprostinilEarly phase 1RecruitingValley Health SystemSep 24, 2026
      A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)TreprostinilPhase 3RecruitingInsmed IncorporatedSep 4, 2026
      A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral SelexipagEpoprostenol, Selexipag, TreprostinilPhase 4RecruitingLiquidia Technologies, Inc.Aug 12, 2026
      A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon AttacksEpoprostenol, TreprostinilPhase 2Not yet recruitingLiquidia Technologies, Inc.Aug 5, 2026
      TREPROSTINIL in Pulmonary Hypertension: Evidence and Clinical TrendsTreprostinil—Not yet recruitingAOP Orphan Pharmaceuticals AGJul 30, 2026
      Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial HypertensionEpoprostenol, Iloprost, SelexipagPhase 4RecruitingUniversity of Sao Paulo General HospitalJul 20, 2026
      Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO)Epoprostenol, SelexipagNot applicableNot yet recruitingUniversity of AlbertaJul 14, 2026
      A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentTreprostinilPhase 1RecruitingInsmed IncorporatedJun 11, 2026
      A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)EpoprostenolPhase 4RecruitingMerck Sharp & Dohme LLCMay 22, 2026
      Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell DiseaseIloprostPhase 3Not yet recruitingUniversity Hospital, RouenMar 27, 2026
      AIRDROP: Can we Improve Adherence to Inhaled Treatment for Pulmonary Arterial Hypertension?IloprostNot applicableRecruitingUniversity of Sao Paulo General HospitalMar 9, 2026
      Long-Term Outcomes of Selexipag in Schistosomiasis-Associated Pulmonary Arterial HypertensionEpoprostenol, Selexipag—Not yet recruitingCaio Júlio César dos Santos FernandesMar 5, 2026
      Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High AltitudeIloprost—Not yet recruitingInstitute of Mountain Emergency MedicineMar 4, 2026
      Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)IloprostPhase 4Not yet recruitingUniversity of Colorado, DenverFeb 20, 2026
      Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial HypertensionIloprost, Selexipag—Not yet recruitingUniversity of Sao Paulo General HospitalJan 21, 2026
      Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD)IloprostNot applicableNot yet recruitingUniversity of Sao Paulo General HospitalDec 4, 2025
      Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter StudySelexipag—RecruitingQianfoshan HospitalDec 31, 2024
      Pulmonary Hypertension: Intensification and Personalisation of Combination RxSelexipagPhase 4Active, not recruitingSheffield Teaching Hospitals NHS Foundation TrustApr 24, 2023
      A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionSelexipagPhase 3RecruitingActelionJan 5, 2022
      A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionRalinepagPhase 3Enrolling by invitationUnited TherapeuticsSep 25, 2018

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1995, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P43119, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.